Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
44 Total results for product and free and sample content found
Datamonitor Healthcare
By Zara Fulton 08 Oct 2017
Alnylam’s high stakes investment in RNAi therapeutics delivers a major short-term win for stakeholders, but long-term commercial success is still in question.
Topic BioPharmaceutical
Datamonitor Healthcare
By Zara Fulton 08 Oct 2017
Allergan’s deal with the Saint Regis Mohawk Tribe will shore up revenue from its top-selling dry eye drug Restasis in the short term.
Topic Company analysis
Datamonitor Healthcare
By Edward Thomason 08 Oct 2017
Positive results from the Phase III PROSPER trial (ClinicalTrials.gov identifier
Topic Cancer
Datamonitor Healthcare
By Oliver Spray 08 Oct 2017
Pharmavitae Analytics expects Gilead’s purchase of Kite to generate long-term growth for Gilead.
Topic Company analysis
Medtech Insight
By Ashley Yeo 04 Apr 2017
Filtering out the background noise, NHS England's chief executive tends to give a straightforward account of the state and the needs of the national health care provider. He did just that in a mid-term update of the NHS Five Year Forward View on March 31.
Datamonitor Healthcare
03 Apr 2017
Roche’s exciting new multiple sclerosis (MS) drug Ocrevus (ocrelizumab) was approved by the US Food and Drug Administration (FDA) on 29 March 2017 (Roche, 2017). The drug is indicated for relapsing-remitting MS (RRMS) on the strength of the two OPERA studies, which showed clear superiority over the current standard of care, Rebif (interferon beta-1a; Merck KGaA/Pfizer).
Topic FDA Multiple Sclerosis
Datamonitor Healthcare
30 Mar 2017
PTC Therapeutics announced the failure of its ACT CF trial of Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF) patients, bringing a halt to any further planned developmental activities in the indication. Although there was a slight treatment effect, Translarna failed to significantly improve pulmonary measures compared to placebo.
Topic Comment wire
Datamonitor Healthcare
By Stephanie Yip 28 Mar 2017
On 21 March 2017, Newron Pharmaceuticals and its partners Zambon and US WorldMeds announced the approval of Xadago (safinamide) for the treatment of Parkinson’s disease (PD) as an add-on therapy to levodopa/carbidopa for patients experiencing “off” periods (BusinessWire, 2017; FDA press release, 2017). This approval was long-awaited by Newron and its US partner, US WorldMeds, as it followed numerous earlier US regulatory setbacks. Newron and its partner are now looking to successfully launch Xadago, but the US approved label fell short of ideal as it did not extend to early-stage PD patients receiving dopamine agonists
Topic Diseases Parkinsons disease
Datamonitor Healthcare
By Jack Allen 27 Mar 2017
Results from the Phase III FOURIER trial in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) find that Repatha treatment results in significant reductions in rates of stroke and myocardial infarction. These positive results have excited physicians, although it is likely that reimbursement will remain strict since payers did not view the results as positively as physicians.
Topic Diseases
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
